Background: To our knowledge no data exists comparing new generation commercially available devices for transfemoral (TF) transcatheter aortic valve implantation (TAVI). Methods: All consecutive patients from our single-center prospective registry with AS treated with TAVI with from Edwards SAPIEN XT™ (SXT) vs. Medtronic CoreValve® with AccuTrak™ delivery sy stem (MCVAT) when the devices became commercially available were included. The study endpoints were according to the Valve Academic Research Consortium (VARC) definitions. Results: In total, 235 patients treated in our center by TF TAVI for severe AS were included: 142 (60.4%) underwent SXT vs. 93 (39.6%) MCVAT. More females (60.6% vs. 43.0%; pϭ0.008) and smaller annulus size (23.2Ϯ1.9 vs. 24.3Ϯ2.0; pϽ0.001) were present in the SXT group. There were no differences between valves in 30-day combined safety endpoint (SXT 26.1% vs. MCVAT 29.7%; pϭ0.558), all-cause mortality (3.1% vs. 6.5%; pϭ0.218), cardiovascular mortality (2.3% vs. 5.4%; pϭ0.214), myocardial infarction (1.4% vs. 2.2%; pϭ0.683) or stroke (0.7% vs. 1.1%; pϭ0.774). Additionally, no differences were observed in life-threatening bleeding (12.4% vs. 20.4%; pϭ0.100) or major vascular complications (12.0% vs. 9.7%; pϭ0.583). Conversely, with SXT there was a lower occurrence of conduction disturbances/arrhythmia (16.5% vs. 36.6%; pϭ0.001) and pacemaker implantation (5.8% vs. 33.3%; pϽ0.001). Of note, a higher device success (96.5% vs. 88.2%; pϭ0.013) was observed with SXT. At median follow-up of 328 (IQR 83-401) days, there was no difference in combined efficacy endpoint (14.8% vs. 9.8%; pϭ0.265) or mortality (8.0% vs. 6.5%; pϭ0.654). Conclusions: In our single center experience, there was a lower incidence of arrhythmia and pacemaker, with higher device success with SXT. Differences in the characteristics of the patients treated with each valve may explain some of these findings. , ⌬Pmean Ͻ 30 mmHg, LVEF Ͻ 30%). Clinical follow-up, echocardiography and measurements of NT-pro-BNP levels were analyzed at 10 days, 4 weeks, 6 month and 1 year after TAVI. Results: Patients with LFLG AS had a higher all-cause mortality at 12 month after TAVI compared to patients with NFHG AS (41% vs. 86%, p Ͻ 0.0001). Nevertheless, surviving patients with LFLG AS showed a significant and steady rise in LVEF after 4 weeks (before 25.8 Ϯ 4.4% vs. 30 days 37.3 Ϯ 13.5%, p Ͻ 0.05), after 6 month (39.1 Ϯ 12%) and 1 year (51.7 Ϯ 4.6%) and a reduction of NT-pro-BNP (before 11956 Ϯ 8094 ng/L vs. 12 month 1832 Ϯ 1261 ng/L, pϭn.s.). Furthermore, these patients showed reduced symptoms of heart failure resulting in an improved NYHA functional class (LFLG vs. NFHG: ⌬4 weeks: Ϫ1.1 Ϯ 0.8 vs. Ϫ1.2 Ϯ 0.8; pϭn.s.; ⌬6 month: Ϫ1.4 Ϯ 0.5 vs. Ϫ1.3 Ϯ 0.8; pϭn.s.; ⌬12 month: Ϫ1.7 Ϯ 0.5 vs. Ϫ1.2 Ϯ 0.8; pϭn.s.). Conclusions: This study shows that the all-cause mortality, 12 month after TAVI in patients with LFLG AS is notably high. However, surviving patients presented an enormous improvement in myocardial function and a high clinical benefit. . Clinical follow-up, echocardiography and measurements of NT-pro-BNP levels were analyzed at 10 days, 4 weeks, 6 month and 1 year after TAVI. Results: Patients with PLFLG AS had a similiar all-cause mortality at 12 month after TAVI compared to patients with NFHG AS (85% vs. 85.6%, pϭ0.771). The LVEF decreased slightly but significant after 4 weeks (before 60.1 Ϯ 1.9% vs. 4 weeks 57.5 Ϯ 5.5%, pϭ0.049), but remained stable after 6 month (57.6 Ϯ 5.1%) and 1 year (56.9 Ϯ 5.7%). Furthermore, patients with PLFLG AS showed slightly high values of NT-pro-BNP at baseline but a similar reduction over time (PLFLG: before 3845 Ϯ 2966 ng/L vs. 1 year 2260 Ϯ 1814 ng/L, pϭ0.079) in conjunction to reduced symptoms of heart failure. NYHA functional capacity improved similar between both groups (PLFLG vs. NFHG: ⌬4 weeks: Ϫ1 Ϯ 0.7 vs. Ϫ1.2 Ϯ 0.8; pϭn.s.; ⌬6 month: Ϫ0.9 Ϯ 0.7 vs. Ϫ1.3 Ϯ 0.8; pϭn.s.; ⌬12 month: Ϫ1.3 Ϯ 1 vs. Ϫ1.2 Ϯ 0.8; pϭn.s.). Conclusions: This study shows that patients with PLFLG AS have a similar benefit after TAVI as patients with NFHG AS and should no longer be withheld from TAVI procedures.
Background: Previous studies showed that patients with impaired left ventricular (LV) function and low-flow, low-gradient (LFLG) aortic stenosis (AS) are associated with high operative risk and poor long-term outcome after surgical aortic valve replacement. The aim of this study was to investigate the clinical outcome of LFLG AS after transcatheter aortic valve implantation (TAVI). Methods: 450 consecutive patients in high operative risk underwent TAVI with the Medtronic Corevalve (Medtronic, Minneapolis, MN, USA) or Edwards Sapien (Edwards Lifesience, Irvine, CA, USA) prostheses at our institution between June 2008 and February 2012. Full data of 341 patients was collected. Of these, 190 patients presented with normal-flow, high gradient (NFHG) AS (aortic surface area (ASA) Ͻ 1.0 cm 2 , mean gradient (⌬Pmean) Ͼ 30 mmHg, LV ejection fraction (LVEF) Ͼ 50%) and 26 patients with LFLG AS (ASA Ͻ 1.0 cm 2 , ⌬Pmean Ͻ 30 mmHg, LVEF Ͻ 30%). Clinical follow-up, echocardiography and measurements of NT-pro-BNP levels were analyzed at 10 days, 4 weeks, 6 month and 1 year after TAVI. Results: Patients with LFLG AS had a higher all-cause mortality at 12 month after TAVI compared to patients with NFHG AS (41% vs. 86%, p Ͻ 0.0001). Nevertheless, surviving patients with LFLG AS showed a significant and steady rise in LVEF after 4 weeks (before 25.8 Ϯ 4.4% vs. 30 days 37.3 Ϯ 13.5%, p Ͻ 0.05), after 6 month (39.1 Ϯ 12%) and 1 year (51.7 Ϯ 4.6%) and a reduction of NT-pro-BNP (before 11956 Ϯ 8094 ng/L vs. 12 month 1832 Ϯ 1261 ng/L, pϭn.s.). Furthermore, these patients showed reduced symptoms of heart failure resulting in an improved NYHA functional class (LFLG vs. NFHG: ⌬4 weeks: Ϫ1.1 Ϯ 0.8 vs. Ϫ1.2 Ϯ 0.8; pϭn.s.; ⌬6 month: Ϫ1.4 Ϯ 0.5 vs. Ϫ1.3 Ϯ 0.8; pϭn.s.; ⌬12 month: Ϫ1.7 Ϯ 0.5 vs. Ϫ1.2 Ϯ 0.8; pϭn.s.). Conclusions: This study shows that the all-cause mortality, 12 month after TAVI in patients with LFLG AS is notably high. However, surviving patients presented an enormous improvement in myocardial function and a high clinical benefit. Background: Previous studies showed that the paradoxical low-flow, low-gradient (PLFLG) aortic stenosis (AS) is a highly challenging condition in terms of diagnostics and therapy. Moreover, this subgroup demonstrates an increased all-cause mortality if treated medically compared to surgically treated patients. The aim of this study was to investigate the clinical outcome and mortality in patients with PLFLG AS after transcatheter aortic valve implantation (TAVI). . Clinical follow-up, echocardiography and measurements of NT-pro-BNP levels were analyzed at 10 days, 4 weeks, 6 month and 1 year after TAVI. Results: Patients with PLFLG AS had a similiar all-cause mortality at 12 month after TAVI compared to patients with NFHG AS (85% vs. 85.6%, pϭ0.771). The LVEF decreased slightly but significant after 4 weeks (before 60.1 Ϯ 1.9% vs. 4 weeks 57.5 Ϯ 5.5%, pϭ0.049), but remained stable after 6 month (57.6 Ϯ 5.1%) and 1 year (56.9 Ϯ 5.7%). Furthermore, patients with PLFLG AS showed slightly high values of NT-pro-BNP at baseline but a similar reduction over time (PLFLG: before 3845 Ϯ 2966 ng/L vs. 1 year 2260 Ϯ 1814 ng/L, pϭ0.079) in conjunction to reduced symptoms of heart failure. NYHA functional capacity improved similar between both groups (PLFLG vs. NFHG: ⌬4 weeks: Ϫ1 Ϯ 0.7 vs. Ϫ1.2 Ϯ 0.8; pϭn.s.; ⌬6 month: Ϫ0.9 Ϯ 0.7 vs. Ϫ1.3 Ϯ 0.8; pϭn.s.; ⌬12 month: Ϫ1.3 Ϯ 1 vs. Ϫ1.2 Ϯ 0.8; pϭn.s.). Conclusions: This study shows that patients with PLFLG AS have a similar benefit after TAVI as patients with NFHG AS and should no longer be withheld from TAVI procedures.
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Acute assessment of transcatheter aortic valve performance after implantation into degenerated aortic surgical bioprostheses Background: Transcatheter aortic valve implantation into failing aortic xenografts is increasingly accepted as a new treatment option for patients in need of re-do open heart surgery. Aim of the study was to compare the acute transvalvular hemodynamics between the Medtronic Corevalve (MCV) prosthesis and the Edwards SAPIEN-valve (ESV) after valve-in-valve implantation (ViVI). Methods: A total of 24 pts (70.8% male, aged 72.6Ϯ6.7 years, mean logES 32.2Ϯ19.4%) underwent a transfemoral transcatheter ViVI for a failing aortic xenograft at our institution. Due to the high frequency of small surgical valves (outer diameter -OD21mm: nϭ11; 23mm nϭ8; 25mm nϭ2; Ն27mm nϭ3) ViVI was predominantly done with the MCV (17pts; 71%) compared to ESV (7pts; 29%: Edwards Sapien nϭ2, Sapien XT nϭ5). Results: Procedural success rate was 87.5%, with 1 pt. displaying moderate aortic regurgitation (deep implanted MCV) and 2 pts. in need of a second MCV due to valve embolisation into the ascending aorta (after attempting a high implantation within small surgical xenografts, both with an OD of 21mm). Thirty-day-mortality was 0%. The average mean aortic valve gradient (dPmean) decreased significantly after ViVI (30.6Ϯ14 vs. 14.3Ϯ6.1 mmHg). Acute hemodynamic data was significantly superior with MCV implanted into xenografts with an ODՅ 23mm (MCV nϭ13: dPmean 12.0Ϯ3.9 mmHg; ESV nϭ3: dPmean 25.6Ϯ2.51 mmHg, pϭ0.02) and severe patient prosthesis mismatch was more likely with ESV (indexed effective orifice area: 0.64Ϯ0.19 vs. 0.86Ϯ0.16, pϭ0.04). The significantly higher gradient with ESV vs. MCV after ViVI into xenografts with an OD of Յ23mm was confirmed by comparison of pooled and recently published data of nϭ64 ESV (Pmean 17.8Ϯ8.4 mmHg; pϭ0.009).
Conclusions:
The low 30d mortality suggests that percutaneous transcatheter ViVprocedures for failing bioprosthetical aortic valves is an effective treatment option for high-risk surgical patients. The MCV should be considered as the first choice in small surgical xenografts (OD Յ 23mm) due to lower remaining transvalvular gradients. Nevertheless, the more demanding implantation with MCV indicates that a smaller MCV-prosthesis (i.e. 23mm) is urgently needed to increase the safety of ViVI.
TCT-847
Adequate choice of the post dilatation balloon size in patients undergoing TAVI based on the CT scan analysis . 74 were treated with post dilatation for residual AR following valve implantation. In this study, 68 were analyzed after excluding 6 patients due to unavailable data. Results: Mean age was 79Ϯ6.2 yrs. Male gender was 42 (61.7%). Mean logistic Euroscore and STS score were 25.2Ϯ17.3 and 9.1Ϯ9.1, respectively. Mean grades of aortic regurgitation at baseline, before and after post dilatation were 1.3Ϯ1.1, 2.3Ϯ0.7 and 0.8Ϯ0.6, respectively. CT scan analysis showed annular coronal diameter 26Ϯ2mm, sagittal diameter 22Ϯ3mm, mid-sinusal diameter 36Ϯ4mm, sinus-tubular junction 27Ϯ5mm, annular eccentricity index 0.9Ϯ0.1. Mean number of calcified commisures 1.9Ϯ 1.1, mean number of annular calcium spots 2.3Ϯ1.2. Edwards valve was used in 13 (19.1%), while CoreValve in 55 (80.8%). Mean valve size was 27.1Ϯ2.2 mm. Mean balloon size was 25.6Ϯ2.3mm. Postdilatation was effective in reducing AR by 1 grade in 42 patients (79%). Effective post dilatation was achieved in 100% of patients with a "post dilatation balloon diameter/ coronal diameter ratio" 0.85-1.07. Outcome of post dilatation was not influenced by the annular eccentricity index. AR following postdilatation was more in patients with heavily calcified annulus. 1 patient (1.5%) had annular tear following post dilatation. 30 days echocardiographic follow up showed 1.1Ϯ0.9 AR. Conclusions: Effectiveness of post dilatation is multifactorial and depends mainly on the proper choice of the balloon size, which in terms depends on the annular coronal diameter assessed by CT scan. Since commisural calcification and annular eccentricity index don't influence the outcome of post dilatation, there is no need for aggressive postdilatation to reduce AR after valve implantation.
TCT-848
Clinical Impact Of Paravalvular Leaks On Biomarkers And Survival After Transcatheter Aortic Valve Implantation. Background: There is accumulating evidence that up to 20 % of the implanted devices after TAVI are associated with a significant degree of paravalvular leaks (PVL), but the clinical impact of PVL is still insufficiently explored. Methods: A total of 355 patients with severe aortic valvulare stenosis (AVS) were treated by TAVI (Corevalve n ϭ 222, Edwards Sapien n ϭ 133). Survival, NT-pro-BNP and the grade of PVL were quantified up to 12 months after implantation. Results: Technical success rate was 97 %. Thirty-day mortality was 9.6%. Postprocedural transvalvular aortic regurgitation was seen only in a minority of cases (5%), whereas PVL were frequently observed (grade: Ͻ1ϩ in 58.2%, Ն1ϩ Ϫ Ͻ2ϩ in 33.9%, and Ն2ϩ in 7.9%). There was a clear relation-ship between PVL and adverse outcome (p Ͻ0.001). After a transient increase NT-pro-BNP showed a significant decline. Interestingly, a PVL Ն2ϩ was associated with a much higher rise in NT-pro-BNP compared to the other groups (p Ͻ0.01), and a post-procedural increase in NT-pro-BNP by more than 1640ng/L was associated with a significant increase in rate of death (p Ͻ0.01).
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